Reports Corner

THERAPEUTIC CLASS OVERVIEW : PSORIASIS – PLAQUE PSORIASIS & PSORIATIC ARTHRITIS : NOVEL ORAL DRUGS
AND BIO...
Description
Description
Over the last decades, therapeutic options for Plaque Psoriasis
(PsO) and Psoriatic Arthritis (PsA...
Brief Summary
Brief Summary
Over the last decades, therapeutic options for Plaque Psoriasis
(PsO) and Psoriatic Arthritis ...
Brief Summary
Brief Summary
We believe there is an ample room for an efficacious affordable
therapy to tap the mild to mod...
Table of Contents
Table of Contents
Therapeutic Class Overview:
Psoriasis – Plaque Psoriasis & Psoriatic Arthritis

Novel ...
Table of Contents
Table of Contents
4. Pipeline – Biologics Products 10-23
4.1. IL-12 and IL-23 inhibitors 10-14
4.1.1. St...
Table of Contents
Table of Contents
5.1. Targeting JAK-STATs 24-28
5.1.1. Tofacitinib
5.1.2. LY3009104
5.1.3. INCB39110
5....
Table of Contents
Table of Contents
5.2.1. OTEZLA
5.3. Other Targets 30-35
5.3.1. Sotrastaurin
5.3.2. LAS41008
5.3.3. Vocl...
Table of Contents
Table of Contents
6.3. DRM02
6.4. Xantryl
6.5. INCB18424
6.6. AN2728
6.7. MOL4249
6.8. DLX105
7. Commerc...
For more information
For more information
For more information please visit our website
https://www.reportscorner.com/repo...
RC

Thank You
Thank You

Contact us: contact@reportscorner.com
www.reportscorner.com

Reports Corner
Upcoming SlideShare
Loading in …5
×

Therapeutic class overview psoriasis – plaque psoriasis & psoriatic arthritis novel oral drugs and biologics to change future treatment paradigm - ReportsCorner

1,242 views

Published on

Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients’ pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients.

https://www.reportscorner.com/reports/37923/THERAPEUTIC-CLASS-OVERVIEW-:-PSORIASIS-%E2%80%93-PLAQUE-PSORIASIS-&-PSORIATIC-ARTHRITIS-:-NOVEL-ORAL-DRUGS-AND-BIOLOGICS-TO-CHANGE-FUTURE-TREATMENT-PARADIGM/

Published in: News & Politics
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,242
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Therapeutic class overview psoriasis – plaque psoriasis & psoriatic arthritis novel oral drugs and biologics to change future treatment paradigm - ReportsCorner

  1. 1. Reports Corner THERAPEUTIC CLASS OVERVIEW : PSORIASIS – PLAQUE PSORIASIS & PSORIATIC ARTHRITIS : NOVEL ORAL DRUGS AND BIOLOGICS TO CHANGE FUTURE TREATMENT PARADIGM RC
  2. 2. Description Description Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients’ pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients. www.reportscorner.com Reports Corner
  3. 3. Brief Summary Brief Summary Over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients’ pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases one drug does not fit the bill for all the patients. The lack of targeted immune therapies other than TNF-α inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc). Pfizer launched the first oral Rheumatoid Arthritis (RA) drug –Xeljanz (tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics. In the last couple of years, the face of healthcare has been changing due to challenges – quality and its affordability and accessibility to the providers and patients. www.reportscorner.com Reports Corner
  4. 4. Brief Summary Brief Summary We believe there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expect few potential launches in 2014-15 (OTEZLA – apremilast, Xeljanz – tofacitinib) and onwards. In this report, we highlight the novel targets – oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compare their clinical trials data, and their commercial potential! www.reportscorner.com Reports Corner
  5. 5. Table of Contents Table of Contents Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis Novel Oral drugs and Biologics to Change Future Treatment Paradigm Table of Contents Chapters Title Pg No. 1. Executive Summary 2 2. Unmet Need in Psoriasis 3 2.1. Limitations of Anti-TNFs 2.2. Scope for Entrants with Better Efficacy and Safety Profiles 3. Specific Unmet Need and Emerging Therapies 7 3.1. Plaque Psoriasis 3.2. Psoriatic Arthritis www.reportscorner.com Reports Corner
  6. 6. Table of Contents Table of Contents 4. Pipeline – Biologics Products 10-23 4.1. IL-12 and IL-23 inhibitors 10-14 4.1.1. Stelara 4.1.2. tildrakizumab (MK-3222/ SCH 900222) 4.1.3. Guselkumab (CNTO 1959) 4.1.4. Fezakinumab (ILV-094) 4.2. Interleukin-17 (IL-17) and Receptor (IL-17RA) 14-19 4.2.1. Secukinumab 4.2.2. Ixekizumab (LY2439821) 4.2.3. Brodalumab (AMG 827) 4.3. Other Targets 19-22 4.3.1. Cimzia 4.3.2. Itolizumab 4.3.3. Tregalizumab 5. Pipeline – Oral Treatment 24-35 www.reportscorner.com Reports Corner
  7. 7. Table of Contents Table of Contents 5.1. Targeting JAK-STATs 24-28 5.1.1. Tofacitinib 5.1.2. LY3009104 5.1.3. INCB39110 5.1.4. ASP015K 5.1.5. GSK2586184 Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis Novel Oral drugs and Biologics to Change Future Treatment Paradigm Table of Contents Chapters Title Pg No. 5.2. Phosphodiesterases 4 (PDE4) Inhibitor 28-30 www.reportscorner.com Reports Corner
  8. 8. Table of Contents Table of Contents 5.2.1. OTEZLA 5.3. Other Targets 30-35 5.3.1. Sotrastaurin 5.3.2. LAS41008 5.3.3. Voclosporin 5.3.4. LLL 3348 5.3.5. CF101 5.3.6. Ponesimod 5.3.7. VB-201 5.3.8. FP187 5.3.9. GSK-2245840 5.3.10. IMO-8400 6. Pipeline – Topical Treatments 35-39 6.1. M518101 6.2. CT327 www.reportscorner.com Reports Corner
  9. 9. Table of Contents Table of Contents 6.3. DRM02 6.4. Xantryl 6.5. INCB18424 6.6. AN2728 6.7. MOL4249 6.8. DLX105 7. Commercial Outlook 39-40 8. Disease Overview 41-47 8.1. Etiology and Pathophysiology of Psoriasis 8.2. Types of Psoriasis 8.3. Treatment Efficacy Tools 9. Current Treatment Options 48-54 10. Treatment Guidelines For PsA 55 www.reportscorner.com Reports Corner
  10. 10. For more information For more information For more information please visit our website https://www.reportscorner.com/reports/37923/THERAPEUTIC-CLASS-OVERVIEW-:PSORIASIS-%E2%80%93-PLAQUE-PSORIASIS-&-PSORIATIC-ARTHRITIS-:-NOVELORAL-DRUGS-AND-BIOLOGICS-TO-CHANGE-FUTURE-TREATMENT-PARADIGM/ www.reportscorner.com Reports Corner
  11. 11. RC Thank You Thank You Contact us: contact@reportscorner.com www.reportscorner.com Reports Corner

×